Letter to the Editor from Raschi et al.: "Endocrine adverse reactions of tyrosine kinase inhibitors in combination with immune checkpoint inhibitors" [0.03%]
Raschi等人的来信：关于酪氨酸激酶抑制剂与免疫检查点抑制剂联合应用的内分泌不良反应
Emanuel Raschi,Monia Donati,Francesco Salvo et al.
Emanuel Raschi et al.
Response to Letter to the Editor from Raschi et al.: "Endocrine adverse reactions of tyrosine kinase inhibitors in combination with immune checkpoint inhibitors" [0.03%]
对Raschi等人的来信的答复："酪氨酸激酶抑制剂与免疫检查点抑制剂联合使用引起的内分泌不良反应"
Wen Shao,Kaiwei Yang,Difei Lu et al.
Wen Shao et al.
Comparison of Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib with First- and Second-Generation TKIs for Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: A Systematic Review and Bias-Corrected Meta-analysis [0.03%]
ponatinib与首代和二代酪氨酸激酶抑制剂治疗费城染色体阳性急性淋巴细胞白血病的比较：系统评价和偏倚修正 meta 分析
Muhammad Zain Raza,Huzaifa Fayyaz Khwaja,Hafiz Muhammad Ehsan Arshad et al.
Muhammad Zain Raza et al.
Background and objectives: Ponatinib, a third-generation tyrosine kinase inhibitor (TKI), has shown efficacy in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), including cases with and without BCR...
Diet-incorporated saracatinib, a Src tyrosine kinase inhibitor, counteracts diisopropylfluorophosphate (DFP)-induced chronic neurotoxicity in the rat model [0.03%]
以饮食方式给药的Saracatinib(一种Src酪氨酸激酶抑制剂)可改善毒扁豆碱所致大鼠慢性神经毒性症状
Suraj S Vasanthi,Nyzil Massey,Christina Meyer et al.
Suraj S Vasanthi et al.
Acute exposure to diisopropylfluorophosphate (DFP), an organophosphate nerve agent, induces status epilepticus (SE) and epileptogenesis despite treatment with countermeasures immediately after exposure. Epileptogenesis is characterized by i...
ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC [0.03%]
ZEB2上调调节TAMs向免疫抑制状态极化以促进表皮生长因子受体酪氨酸激酶抑制剂耐药非小细胞肺癌进展
Yunhuan Liu,Yong Yu,Congli Hu et al.
Yunhuan Liu et al.
Aim: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment approach for NSCLC. However, the effectiveness of ICI therapy in patients with EGFR-driven NSCLC, particularly those resistant to EGFR-TKI, has been disappointing. T...
Treatment of Retinal/Choroidal Vascular Diseases by Sustained Delivery of VEGF Receptor Tyrosine Kinase Inhibitors [0.03%]
通过持续递送VEGF受体酪氨酸激酶抑制剂治疗视网膜和脉络膜血管疾病
Dilsher S Dhoot
Dilsher S Dhoot
Purpose: To review current investigational strategies utilizing sustained delivery of VEGF receptor tyrosine kinase inhibitors (TKIs) for the treatment of retinal and choroidal vascular diseases. ...
Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer [0.03%]
非小细胞肺癌中表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的分子机制
Zhenfang Du,Hongfei Kan,Jinghan Sun et al.
Zhenfang Du et al.
Tyrosine kinase inhibitors (TKIs) have revolutionized the management of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Despite the initially favorable outcomes, these patients inevitably acquire resistanc...
EGFR mutations in non-small cell lung cancer: Classification, characteristics and resistance to third-generation EGFR-tyrosine kinase inhibitors (Review) [0.03%]
非小细胞肺癌表皮生长因子受体突变的分类、特征及其对第三代表皮生长因子受体-酪氨酸激酶抑制剂产生耐药性的研究（综述）
Zhe Tian,Lilan Cen,Feng Wei et al.
Zhe Tian et al.
Mutations in EGFR (mEGFRs) in non-small cell lung cancer (NSCLC) are key factors driving tumor development and treatment response. The present article aimed to review the classification, characteristics and molecular mechanisms of resistanc...
Corrigendum to "The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells" [Biomed. Pharmacother. 176 (2024) 116892] [0.03%]
关于“使用酪氨酸激酶受体抑制剂和老药联合疗法靶向患者来源的胶质母细胞瘤干细胞”一文的勘误[Biomed. Pharmacother. 176 (2024) 116892]
Malgorzata Kucinska,Julia Pospieszna,Jing Tang et al.
Malgorzata Kucinska et al.
耗时 0.32946 秒，为您在
48229835
条记录里面共找到 9995 篇文章 [XML]